Norwich Pharmaceuticals, Inc. has formed a strategic alliance with Emerson Resources, Inc. focused on bringing together the capabilities of the two companies in order to provide a broader range of services to the industry.

Norwich recently completed an expansion of its capabilities and services focused on full product lifecycle support, with a concentration in the area of new product development. Chris Calhoun, president of Norwich Pharmaceuticals, commented, “This alliance builds on our long-standing relationship with Emerson, and on our new full-service capabilities at Norwich, offering a clear path to commercialization for the clients of both our companies.”

Adolfo Gomez, president of Emerson Resources, said, “Our two companies were formed at about the same time, we’ve grown together, and we’ve been working together for years. Being relatively close to one another, we have been able to quickly access and share each other’s resources. By leveraging our collective experience and combined production capacity, both companies can bring faster, more flexible full-service capabilities to our customers, without the burdens of added bureaucracy that often hamper our competitors.”

Emerson will provide early stage development and clinical trial material manufacturing, as well as analytical services, and support of formulation development, method qualification for pilot clinical trials and analytical method transfer. Phase III and commercial batches will be manufactured exclusively at the Norwich facility, with full regulatory support for compiling INDs/NDA’s/ANDA’s and marketing applications for selected projects.

A joint governance team will oversee the alliance and will be responsible for overall performance management and individual project teams executing separate initiatives. Joint projects will be managed through a single point of contact.